名稱 | BCR-ABL1 M351T/BaF3 |
型號(hào) | CBP73323 |
報(bào)價(jià) | ![]() |
特點(diǎn) | BCR-ABL1 [M351T]/BaF3 |
產(chǎn)品搜索
相關(guān)文章
- 腫瘤細(xì)胞到底是如何“轉(zhuǎn)移”的呢?
- TIGIT&PVRIG雙靶點(diǎn)細(xì)胞篩選模型
- 羅氏免疫療法獲FDA批準(zhǔn)治療晚期非小細(xì)胞肺癌(NSCLC)
- 官宣!Ba/F3激酶穩(wěn)定細(xì)胞株&科佰激酶篩選平臺(tái)
- 【新品上線】AXL篩選模型
- ATCC細(xì)胞株培養(yǎng)操作
- 科學(xué)家發(fā)現(xiàn)10個(gè)新的智力障礙易感基因
- 潛力十足的T細(xì)胞療法,我們用得起嗎?
- PD-1/PD-L1:研發(fā)過(guò)剩還是大有可為
- 腫瘤細(xì)胞調(diào)控關(guān)鍵因子和機(jī)制的研究講解
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73323BCR-ABL1 M351T/BaF3

- 詳細(xì)內(nèi)容
CBP73323 | |
I. Introduction | |
Cell Line Name: | BCR-ABL1 [M351T]/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. | |
III. Representative Data | |
1.WB of BCR-ABL1 [M351T]/BaF3 | |
2.Sanger of BCR-ABL1 [M351T]/BaF3 Figure 2. BCR-ABL1 [M351T]/BaF3 Figure 3. BCR-ABL1 [M351T]/BaF3 Fusion | |
3. Anti-proliferation assay Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 M351T Cells (C3). | |